| Issue |
Natl Sci Open
Volume 1, Number 1, 2022
Special Topic: COVID-19: Virus, Immunity and Vaccines
|
|
|---|---|---|
| Article Number | 20220004 | |
| Number of page(s) | 7 | |
| Section | Life Sciences and Medicine | |
| DOI | https://doi.org/10.1360/nso/20220004 | |
| Published online | 25 March 2022 | |
REVIEW
Challenges of COVID-19 vaccination in patients with cancer
1
NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention,
Nanjing
210009,
China
2
Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University,
Nanjing
210009,
China
3
Center for Global Health (CGH), Nanjing Medical University,
Nanjing
211166,
China
4
Shanghai Institute of Infectious Disease and Biosecurity,
Shanghai
200433,
China
* Corresponding author (email: jszfc@vip.sina.com)
Received:
9
October
2021
Revised:
9
January
2022
Accepted:
19
January
2022
Patients with cancer are at increased risk of SARA-CoV-2 infection or developing severe COVID-19 cases due to malignancy or immunosuppressive therapy, but they are generally excluded from the target population for COVID-19 vaccination. In general, inactivated vaccines are safe and immunogenic for patients with cancer, but live attenuated vaccines are not recommended. The study suggested that the safety of the mRNA COVID-19 vaccine in patients with cancer is similar to that in healthy people, but immunogenicity is slightly weaker, and a booster dose may be needed. This paper aims to summarize the results of COVID-19 vaccine clinical studies conducted in patients with cancer worldwide and the relevant guidelines released by authorities, so as to provide evidence for promoting COVID-19 vaccination for patients with cancer.
Key words: COVID-19 / vaccine / clinical trial / patients with cancer
© The Author(s) 2022. Published by China Science Publishing & Media Ltd. and EDP Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.